Hospital groups sue HHS seeking 340B price transparency now

Sep 11, 2018 - 02:55 PM

The AHA, Association of American Medical Colleges, America’s Essential Hospitals, 340B Health and three hospital systems today asked a federal court to order the Department of Health and Human Services to make effective within 30 days a final rule requiring drug companies to disclose the ceiling price for 340B outpatient drugs. HHS has delayed five times the effective date for the rule, required by Congress in 2010. To ensure accuracy and compliance with the 340B drug savings program, the rule also describes how ceiling prices must be calculated and would allow the federal government to levy civil monetary penalties against drug companies that intentionally overcharge 340B providers. 

“As prescription drug prices continue to skyrocket, the 340B program is as crucial as ever in helping hospitals and health systems provide access to health care services for vulnerable patients and communities,” said AHA President and CEO Rick Pollack. “Our lawsuit will promote the transparency and accuracy that the government has found lacking and hold price gouging drug companies accountable.” 

The associations are joined in the suit by hospital plaintiffs Rutland Regional Medical Center in Rutland, Vt.; Genesis HealthCare System in Zanesville, Ohio; and Kearny County Hospital in Lakin, Kan. 
 

Related News Articles

Headline
HHS finalizes rule on 340B Administrative Dispute Resolution process
The Department of Health and Human Services April 18 finalized its rule to establish a 340B Administrative Dispute Resolution process as required under the…
Headline
Senator Thune touts support for telehealth, urges solution-oriented advocacy 
Sen. John Thune, R-S.D., April 16 updated AHA members on progress to extend telehealth waivers, offering hope that a solution will arise in end-of-year…
Headline
AHA comments on draft Senate bill to clarify, protect 340B program 
AHA March 26 submitted comments on a discussion draft of the SUSTAIN 340B Act, legislation proposed in the Senate to clarify Congress’ intent in creating the…
Headline
New Healthsperien report finds that 340B drug discounts are a small share of drug company revenues
AHA March 12 released a new report from Healthsperien on discounts to 340B hospitals through the 340B Drug Pricing Program relative to drug company revenues…
Headline
As urged by the AHA, 8th Circuit upholds Arkansas law protecting 340B contract pharmacy arrangements
The U.S. Court of Appeals for the 8th Circuit March 12 upheld Arkansas’ 340B Drug Pricing Nondiscrimination Act against a constitutional challenge brought by…
Headline
AHA files brief defending Louisiana 340B contract pharmacy law
AHA Feb. 29 filed a friend-of-the-court brief in support of a Louisiana law that prohibits drug companies from denying Louisiana hospitals the same 340B…